Literature DB >> 9367379

Mutations which alter the DNA binding properties of the herpes simplex virus type 1 transactivating protein Vmw175 also affect its ability to support virus replication.

K E Allen1, R D Everett.   

Abstract

The crucial role of herpes simplex virus type 1 immediate early protein Vmw175 (ICP4) in the regulation of all classes of viral genes has been established by extensive analysis of temperature-sensitive, insertion and deletion mutants. It has long been known that Vmw175 binds to selected DNA sequences, and recent studies have shown that it interacts with components of the basal transcription machinery. However, the role of DNA binding in its mechanism of action has been controversial. Despite the presence of Vmw175 recognition sites at numerous locations throughout the viral genome, it has proved difficult to establish that these sites are important for the activation of early and late promoters. In this study we have analysed the ability of a large number of insertion and single point mutant derivatives of Vmw175 to bind to DNA and to support virus replication. Vmw175 mutants which were unable to bind to DNA were also incapacitated in terms of their ability to activate gene expression in transfection assays and to complement the growth of a Vmw175 deletion mutant virus. These results strongly support the hypothesis that interaction with DNA is an essential feature of the mechanism of action of Vmw175.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367379     DOI: 10.1099/0022-1317-78-11-2913

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  DNA-dependent oligomerization of herpes simplex virus type 1 regulatory protein ICP4.

Authors:  Ruhul H Kuddus; Neal A DeLuca
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

2.  The herpes viral transcription factor ICP4 forms a novel DNA recognition complex.

Authors:  Richard B Tunnicliffe; Michael P Lockhart-Cairns; Colin Levy; A Paul Mould; Thomas A Jowitt; Hilary Sito; Clair Baldock; Rozanne M Sandri-Goldin; Alexander P Golovanov
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

3.  ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II.

Authors:  M C Long; V Leong; P A Schaffer; C A Spencer; S A Rice
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Oligomerization of ICP4 and rearrangement of heat shock proteins may be important for herpes simplex virus type 1 prereplicative site formation.

Authors:  Christine M Livingston; Neal A DeLuca; Dianna E Wilkinson; Sandra K Weller
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

5.  Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo.

Authors:  Bunji Sato; Hideki Ito; Stewart Hinchliffe; Marvin H Sommer; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Herpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replication.

Authors:  G Zachos; M Koffa; C M Preston; J B Clements; J Conner
Journal:  J Virol       Date:  2001-03       Impact factor: 6.549

7.  Mitotic transcription repression in vivo in the absence of nucleosomal chromatin condensation.

Authors:  C A Spencer; M J Kruhlak; H L Jenkins; X Sun; D P Bazett-Jones
Journal:  J Cell Biol       Date:  2000-07-10       Impact factor: 10.539

8.  Quantitative Trait Locus Based Virulence Determinant Mapping of the HSV-1 Genome in Murine Ocular Infection: Genes Involved in Viral Regulatory and Innate Immune Networks Contribute to Virulence.

Authors:  Aaron W Kolb; Kyubin Lee; Inna Larsen; Mark Craven; Curtis R Brandt
Journal:  PLoS Pathog       Date:  2016-03-10       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.